Evidence map›Paper›PMID 35372043›Full record

ArticleFrontiers in oncology2022

Modulation of ERCC1-XPF Heterodimerization Inhibition

Claudia Weilbeer, David Jay, James C Donnelly, Francesco Gentile, Feridoun Karimi-Busheri, Xiaoyan Yang, Rajam S Mani, Yaping Yu, Ahmed H Elmenoufy, Khaled H Barakat and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Targeting the DNA Damage Response for Cancer Therapy.International journal of molecular sciences · 2023
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Claudia WeilbeerDepartment of Chemistry, University of Alberta, Edmonton, AB, Canada.
David JayDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
James C DonnellyDepartment of Chemistry, University of Alberta, Edmonton, AB, Canada.
Francesco GentileDepartment of Physics, University of Alberta, Edmonton, AB, Canada.
Feridoun Karimi-BusheriDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Xiaoyan YangDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Rajam S ManiDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Yaping YuCentre for Genome Engineering, University of Calgary, Calgary, AB, Canada.
Ahmed H ElmenoufyDepartment of Chemistry, University of Alberta, Edmonton, AB, Canada.
Khaled H BarakatFaculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.
Jack A TuszynskiDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Michael WeinfeldDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Frederick G WestDepartment of Chemistry, University of Alberta, Edmonton, AB, Canada.
University of Alberta · CAUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of DNA repair enzymes is an attractive target for increasing the efficacy of DNA damaging chemotherapies. The ERCC1-XPF heterodimer is a key endonuclease in numerous single and double strand break repair processes, and inhibition of the heterodimerization has previously been shown to sensitize cancer cells to DNA damage. In this work, the previously reported ERCC1-XPF inhibitor 4 was used as the starting point for an

Indexed as

computer aided drug design (CADD)DNA repairERCC1-XPF small molecule inhibitorsionizing and UV irradiationproximity ligation assay

Identifiers

PMID35372043
PMCPMC8968952
OpenAlexW4220877412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.